ABSTRACT
The fibrous annulus of the mitral valve defines the functional orifice and anchors the anterior and posterior leaflets, playing an important role in normal cardiovascular physiology and valvular function. We derived automated estimates of mitral valve annular diameter in the 4-chamber view from 32,220 MRI images from the UK Biobank at ventricular systole and diastole as the basis for genome wide association studies. Mitral annular dimensions correspond to previously described anatomical norms and GWAS inclusive of four population strata identify ten loci, including novel loci (GOSR2, ERBB4, MCTP2, MCPH1) and genes related to cardiac contractility (BAG3, TTN, RBFOX1). ATAC-seq of primary mitral valve tissue localize multiple variants to regions of open chromatin in biologically relevant cell types and rs17608766 to an algorithmically predicted enhancer element in GOSR2. We observed strong genetic correlation with measures of contractility and mitral valve disease, and clinical correlations with heart failure, cerebrovascular disease, and ventricular arrythmias. A polygenic score of mitral valve annular diameter in systole was predictive of risk mitral valve prolapse across four cohorts (Odds ratio 1.19 per SD increase in polygenic score, 95% confidence interval 1.14 to 1.24, p=4.9E-11). In summary genetic and clinical studies of mitral valve annular diameter reveal new genetic determinants of mitral valve biology while highlighting known and previously unrecognized clinical associations. Polygenic determinants of mitral valve annular diameter may represent an independent risk-factor for mitral prolapse. Overall, computationally estimated phenotypes derived at scale from medical imaging represent an important substrate for genetic discovery and clinical risk prediction.
Competing Interest Statement
Dr. Priest is an employee and stockholder of BioMarin Pharmaceutical.
Funding Statement
Funding from the NIH R00HL130523 to JRP. Stanford MCHRI Seed Grant to CGT.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work employed deidentified data from the UK Biobank. Ethical approval was granted by the NHS National Research Ethics Service (ref: 11/NW/0382). IRB exemption was granted for the use of de-identified imaging, genetic, and clinical data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data Availability
UK Biobank data is available to the public. Penn Biobank and French data from GWAS of Mitral Prolapse are available from the primary authors of those studies upon request.
